Exchange: NASDAQ·Updated 04:22 PM EDT
OPK logo

OPKOpko Health Inc

$1.49
$0.02
(1.64%)
Today
Closed $1.24
$0.25
(20.16%)
After Hours
EarningsJul 27
Mkt Cap$921.21M
Vol2.63M
News
all
press releases
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health's growth outlook rests on RAYALDEE, BioReference gains and partnerships, though losses and pipeline risks persist.
Zacks
More News
IQVIA (IQV) Up 3.2% Since Last Earnings Report: Can It Continue?
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
OPKO Health (OPK) Up 17.1% Since Last Earnings Report: Can It Continue?
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health leans on RAYALDEE and key partnerships, such as BioReference and 4Kscore, as it ramps toward mid-2026 diagnostics breakeven.
Zacks
OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Recommendation of "Hold" by Brokerages
OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) has earned an average recommendation of 'Hold' from the six brokerages that are covering the company, Marketbeat reports. One investment analyst has...
MarketBeat
HC Wainwright Boosts Earnings Estimates for OPKO Health
OPKO Health, Inc. (NASDAQ:OPK - Free Report) - Analysts at HC Wainwright lifted their FY2026 earnings estimates for shares of OPKO Health in a research note issued to investors on Wednesday, April...
MarketBeat
Q1 Earnings Estimate for OPKO Health Issued By HC Wainwright
OPKO Health, Inc. (NASDAQ:OPK - Free Report) - Analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of OPKO Health in a research report issued to clients and investors on Wednesday, April 29th. HC Wainwright analyst Y. Chen expects that the biotechnology compa...
MarketBeat
OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y
OPK's Q1 earnings match estimates as pharma product sales rose, but revenue slides 25.7% after a smaller BioReference diagnostics base.
Zacks
OPKO Health (NASDAQ:OPK) Hits New 1-Year Low - Should You Sell?
OPKO Health (NASDAQ:OPK) Reaches New 1-Year Low - What's Next...
MarketBeat
OPKO Health Q1 2026 Earnings Call: Complete Transcript
read more...
Benzinga
<
1
2
>

Advertisement|Remove ads.